

# L.D. Collins & Co. Ltd.:

## Methodological note for

# HCP/ORDM/HCO disclosure **2025**

Data year: **2025**

Year of publication: 2026

## INTRODUCTION

L.D. Collins & Co. Ltd. is a pharmaceutical company specialising in the area of women's health. To conduct its business, L.D. Collins engages legitimately with healthcare professionals (HCPs), other relevant decision makers (ORDMs) and healthcare organisations (HCOs). Depending on the activity provided or received, a direct or indirect transfer of value (TOV) may be attached.

The Association of British Pharmaceutical Industry (ABPI) Code of Practice requires that pharmaceutical companies document and publicly disclose certain TOVs made directly or indirectly to HCPs, ORDMs and HCOs. A TOV is defined as a direct or indirect transfer of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines.

L.D. Collins is committed to disclosing all TOVs to HCPs, ORDMs and HCOs in accordance with its commitment to the ABPI Code of Practice.

Each company providing TOVs is required to publish a note summarising the methodologies used by the company in preparing the disclosures, identifying each category of TOV. This document summarises the methodology for the reporting period **1<sup>st</sup> January 2025 to 31<sup>st</sup> December 2025**. This disclosure report is available for a period of at least three years after its disclosure and its relevant records will be retained for a period of at least five years after the end of the calendar year to which they relate.

## CONTENTS

### 1 Definitions

- 1.1 Recipients
- 1.2 Kind of ToVs

### 2 Disclosure's Scope

- 2.1 Products concerned
- 2.2 Company concerned
- 2.3 Excluded ToVs
- 2.4 ToVs date
- 2.5 Direct ToVs
- 2.6 Indirect ToVs
- 2.7 Non-monetary ToVs
- 2.8 ToVs in case of partial attendances or cancellation and refund
- 2.9 Cross-border activities
- 2.10 R&D
- 2.11 Voluntary disclosure

### 3 Specific considerations

- 3.1 Country unique identifier
- 3.2 Self-incorporated HCP
- 3.3 Multi-year agreements
- 3.4 Country specificities
- 3.5 Quality checks

### 4 Data protection legal basis

- 4.1 Consent collection
- 4.2 Legitimate interests

### 5 Form of disclosure

- 5.1 Date of publication
- 5.2 Disclosure platform
- 5.3 Disclosure language

### 6 Disclosure financial data

- 6.1 Currency
- 6.2 VAT included or excluded
- 6.3 Calculation rules

### 7 Additional information

## 1 DEFINITIONS

### 1.1 Recipients

Healthcare Professionals (HCPs) are members of the medical, dental, pharmacy and nursing professions and any other persons who during their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

Other Relevant Decision Makers (ORDMs) include individuals, particularly those with a role within the NHS, who may influence the administration, consumption, prescription, purchase, recommendation, sale, supply or use of medicines but who are not healthcare professionals.

Healthcare Organisations (HCOs) are healthcare, medical or scientific associations or organisations such as hospitals, clinics, foundations, universities or other teaching institutions or learned societies whose business address, place of incorporation or primary place of operation is in Europe, or organisations through which one or more healthcare professionals or other relevant decision makers provide services.

### 1.2 Kind of ToVs

Transfer of Value (ToV) means a direct or indirect transfer of value, whether in cash, in kind or otherwise, made for promotional or non-promotional purposes in connection with the development or sale of medicines.

A direct ToV is one made directly by L.D. Collins & Co. Ltd. to a recipient.

An indirect ToV is one made on behalf of L.D. Collins & Co. Ltd. for the benefit of a recipient through an intermediary where the company knows or can identify the recipient benefiting from the transfer of value.

## 2 DISCLOSURE'S SCOPE

### 2.1 Products concerned

L.D. Collins & Co. Ltd. is a pharmaceutical company specialising in women's health. The disclosures relate to transfers of value associated with activities connected to the development or sale of medicines within this therapeutic area.

### 2.2 Company concerned

This disclosure relates to transfers of value made by **L.D. Collins & Co. Ltd. (LDC)** to healthcare professionals, other relevant decision makers and healthcare organisations.

### **2.3 Excluded ToVs**

Transfers of value not required to be disclosed under the ABPI Code of Practice are excluded. In addition, LDC did not make donations or grants to HCOs and did not sponsor attendance at meetings for HCPs or ORDMs during the **2025** reporting period.

### **2.4 ToVs date**

L.D. Collins discloses transfers of value based on the date the payment was completed, meaning the date the payment was released from the company's bank account.

Due to administrative processes, there may be a delay between approval and payment of a transfer of value. Activities performed at the end of a calendar year may therefore be disclosed in the following reporting period if payment occurs in that year.

For non-financial transfers of value, such as services or benefits in kind, the date used for disclosure purposes is the date on which the agreement to provide the service or benefit was signed.

### **2.5 Direct ToVs**

Direct transfers of value are payments made directly by L.D. Collins & Co. Ltd. to healthcare professionals, other relevant decision makers or healthcare organisations.

### **2.6 Indirect ToVs**

Indirect transfers of value are those made on behalf of L.D. Collins & Co. Ltd. through an intermediary or third party for the benefit of healthcare professionals, other relevant decision makers or healthcare organisations where the company can identify the ultimate beneficiary.

### **2.7 Non-monetary ToVs**

Non-monetary transfers of value may include benefits in kind or services provided without a direct payment. These are disclosed where required under the ABPI Code of Practice.

### **2.8 ToVs in case of partial attendances or cancellation and refund**

L.D. Collins did not sponsor attendance at meetings or conferences for HCPs or ORDMs in **2025**. Therefore, no transfers of value relating to partial attendance, cancellations or refunds were recorded.

### **2.9 Cross-border activities**

Transfers of value are disclosed in the United Kingdom where the recipient has their primary place of practice or registration in the UK.

## **2.10 R&D**

L.D. Collins did not contribute to research and development activities requiring disclosure during the **2025** reporting period.

## **2.11 Voluntary disclosure**

L.D. Collins is committed to transparency and discloses all transfers of value required under the ABPI Code of Practice. No additional voluntary disclosures were made beyond those required by the Code.

# **3 SPECIFIC CONSIDERATIONS**

## **3.1 Country unique identifier**

Where applicable, recipients are identified using available professional or organisational identifiers in accordance with ABPI disclosure requirements.

## **3.2 Self-incorporated HCP**

Where healthcare professionals provide services through an incorporated entity or employer organisation, transfers of value may be disclosed against the relevant healthcare organisation where appropriate.

In **2025**, one healthcare professional requested that fees for a presentation be paid to the healthcare organisation where they were employed, and the payment was therefore disclosed under the HCO category.

## **3.3 Multi-year agreements**

Separate transfers of value relating to the same activity but occurring across different reporting periods are disclosed in the respective year in which the transfer of value occurred based on the payment date.

No accruals are made for disclosure purposes.

## **3.4 Country specificities**

Disclosure practices follow the requirements of the **ABPI Code of Practice** and applicable UK transparency requirements.

## **3.5 Quality Checks**

L.D. Collins performs internal verification processes to ensure the accuracy and completeness of the disclosure data prior to publication.

## 4 DATA PROTECTION LEGAL BASIS

### 4.1 Consent collection

Consent for disclosure is obtained from healthcare professionals through a separate consent form to comply with the UK General Data Protection Regulation (GDPR).

Where consent is not obtained or cannot be obtained, transfers of value are reported in the aggregate section of the disclosure report.

### 4.2 Legitimate interests

Where appropriate and in accordance with applicable legislation and transparency obligations, disclosures may also rely on legitimate interests relating to industry transparency and compliance with the ABPI Code of Practice.

## 5 FORM OF DISCLOSURE

### 5.1 Date of publication

The disclosure is published annually following the end of the reporting year. The **2025** disclosure is published in **2026**.

The disclosure report will remain publicly available for at least three years after publication. Relevant records will be retained for at least five years following the end of the calendar year to which they relate.

### 5.2 Disclosure platform

The disclosure report is published on the L.D. Collins & Co. Ltd. website or other appropriate transparency platform in accordance with ABPI Code requirements.

### 5.3 Disclosure language

The disclosure is published in English.

## 6 DISCLOSURE FINANCIAL DATA

### 6.1 Currency

All transfers of value are reported in **British Pounds Sterling (£)**.

## 6.2 VAT included or excluded

Where applicable, VAT has been excluded from the disclosed values. All disclosed amounts are therefore exclusive of VAT.

## 6.3 Calculation rules

If L.D. Collins made the transfer of value and it is recorded within the company's accounting system, the full value is disclosed.

Where the transfer of value was made by a co-promotion partner and subsequently recharged to L.D. Collins, only the portion paid by L.D. Collins is disclosed.

Transfers of value made directly by the co-promotion partner are disclosed in that partner's own disclosure report.

## 7 ADDITIONAL INFORMATION

L.D. Collins & Co. Ltd. engages with healthcare professionals, other relevant decision makers and healthcare organisations as part of legitimate scientific and educational activities supporting the development and appropriate use of medicines.

The company is committed to transparency and complies with the **ABPI Code of Practice** regarding disclosure of transfers of value.

## LIST OF ABBREVIATIONS

|      |  |
|------|--|
| ABPI | Association of the British Pharmaceutical Industry |
| GDPR | General Data Protection Regulation                 |
| HCO  | Healthcare Organisation                            |
| HCP  | Healthcare professional                            |
| LDC  | L.D. Collins & Co. Ltd                             |
| ORDM | Other relevant decision maker                      |
| R&D  | Research and Development                           |
| TOV  | Transfer of value                                  |